arrowhead läuft - zu recht

Arrowhead Pharmaceuticals to Host Pulmonary R&D Day

Wed, April 27, 2022, 1:30 PM
finance.yahoo.com/news/...als-host-pulmonary-r-113000587.html
ASADENA, Calif., April 27, 2022--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a pulmonary research & development (R&D) day to discuss its emerging pipeline of pulmonary targeted RNA interference (RNAi) therapeutic candidates from 10:00 a.m. to 1:00 p.m. ET on May 26, 2022, in New York City. The R&D day will feature presentations from key opinion leaders, Mario Castro, M.D., MPH (University of Kansas Medical Center) and Matthias Salathe, M.D. (University of Kansas Medical Center), who will discuss the current treatment landscape and unmet medical need in treating patients with muco-obstructive and inflammatory pulmonary diseases.

The R&D day will also feature presentations from the Arrowhead team, who will discuss the company’s proprietary pulmonary Targeted RNAi Molecule (TRiMTM) platform and the therapeutic potential of the investigational RNAi candidates, ARO-MUC5AC and ARO-RAGE, in these disease areas:

   ARO-MUC5AC is designed to reduce expression of mucin 5AC (MUC5AC) as a potential treatment for various muco-obstructive pulmonary diseases

   ARO-RAGE is designed to reduce expression of the receptor for advanced glycation end products (RAGE) as a potential treatment for various obstructive inflammatory pulmonary diseases

Drs. Castro and Salathe, and the Arrowhead team will be available to answer questions following the event.

This event is intended for institutional investors, sell-side research analysts, and business development professionals only. Please RSVP in advance if you plan to attend, as space is limited. To request a seat, please click here to register.

A copy of the presentation materials and a webcast link will be available on the Events and Presentations page under the Investors section of the Arrowhead website.

Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MMP7 for Idiopathic Pulmonary Fibrosis

Wed, August 17, 2022 at 1:30 PM
finance.yahoo.com/news/...y-clearance-initiate-113000051.html

finance.yahoo.com/news/...resents-phase-2-data-210800797.html


wieder sehr gute Ergebnisse.
Und verschiedene Phasen 3 stehen an.
Die gehen ihren Weg und der Kurs wird folgen

Super, ich bin auch deiner Meinung.  

ARWR verkauft Lizenzbeteiligung an Olpasiran

• 
  an $RPRX für 250 Mio. $ und zukünftige Meilensteine
  

www.fiercebiotech.com/biotech/...prized-amgen-partnered-heart

Zahlen für FY22

• Umsatz 243 Mio. $
  
• Verlust 173 Mio. $
  
• Cash 482 Mio. $
  
• MK 2,96 Mrd. $
  

ir.arrowheadpharma.com/news-releases/...2022-year-end-results

Arrowhead Pharmaceuticals Announces $25 Million Milestone Payment from Amgen

Tue, December 20, 2022 at 1:30 PM GMT+1
finance.yahoo.com/news/...announces-25-million-123000951.html

Arrowhead Pharmaceuticals to Present Topline Data from the Phase 2 SEQUOIA Study Evaluating Fazirsiran and Describe Design for Planned Phase 3 Study

Wed, December 21, 2022 at 1:30 PM GMT+1
finance.yahoo.com/news/...present-topline-data-123000512.html
PASADENA, Calif., December 21, 2022--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that on January 9, 2023, at 8:30 a.m. ET, it will present topline data from the SEQUOIA Phase 2 study evaluating fazirsiran and provide an outline of a Phase 3 study that was co-developed with and will be run by Takeda. Fazirsiran is a potential first-in-class investigational RNA interference (RNAi) therapy designed to reduce production of the mutant alpha-1 antitrypsin protein (Z-AAT) as a potential treatment for the rare genetic liver disease associated with alpha-1 antitrypsin deficiency. Fazirsiran is being developed under a collaboration and licensing agreement between Arrowhead and Takeda.

das hört sich gut an.
Top line Daten für die Phase 2 und damit die Phase 3.
Dann wird noch interessant, ob die Behörde Fast Lane genehmigt.

man kann auch sagen: na endlich

Von Ihnen kommen bereits 7 der letzten 20 (oder weniger) positiven Bewertungen für 11fred11.  

aber für den Markt nicht gut genug.
Es wird eine Phase 3 geben- heißt - 2 Jahre noch, dann irgendwann die Zulassung.
Das ist dem Markt zu weit weg.

ir.arrowheadpharma.com/news-releases/...sults-sequoia-phase-2

Jan 9, 2023 11:15 AM EST
ir.arrowheadpharma.com/static-files/...4773-943a-dbacdfb726a0

Arrowhead Pharmaceuticals to Webcast Fiscal 2023 First Quarter Results
finance.yahoo.com/news/...-webcast-fiscal-2023-123000104.html
PASADENA, Calif., January 25, 2023--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 6, 2023, at 4:30 p.m. ET to discuss its financial results for the fiscal 2023 first quarter ended December 31, 2022.

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MMP7 for Treatment of Idiopathic Pulmonary Fibrosis
Feb 2, 2023 at 7:30 AM EST
ir.arrowheadpharma.com/news-releases/...se-12a-study-aro-mmp7

2) IPF patients will need to take this drug for the rest of their lives, and every year you can add another 30k patients in the US alone. The amount of patients that can be added on a yearly basis for this orphan indication will easily rival the number of patients that get added on larger, non-orphan indications, as typical orphan indication increases are around 5% per year (like it is for AAT).

3) Since this is such a serious condition, and an orphan indication, the cost of this drug should easily surpass $75k per year (I'm guessing it could easily go well into the $200k range). Crunch those numbers and you'll see that you'll easily bring in $10B+ in yearly revenue after 3-5 years on the market. And if the drug works, Accelerated Approval after phase 2 is a no-brainer. At that point, analysts would be giving price targets in the $300+/share range based on this one drug alone. That's right, $300+ based on this one drug alone.

So even though it's an orphan indication, it will theoretically take advantage of a larger, non-orphan population, but also benefit at orphan drug pricing levels, especially since there's currently no competition and it's for an incredibly grave condition.

Realize that all has to go right in order for this to happen. We still don't have proof-of-concept for lung, let alone what the knock-down would be for this drug. I'll tell you this, given these circumstances, it is incredibly exciting.
finance.yahoo.com/quote/ARWR/community?p=ARWR

Arrowhead drops as Cantor flags risks to Johnson & Johnson licensing deal
Feb. 06, 2023 2:49 PM ETArrowhead Pharmaceuticals, Inc. (ARWR), JNJBy: Dulan Lokuwithana, SA News Editor
seekingalpha.com/news/...ial&utm_source=twitter_automated

Arrowhead Pharmaceuticals Reports Fiscal 2023 First Quarter Results
Feb 6, 2023 at 4:00 PM EST
ir.arrowheadpharma.com/news-releases/...al-2023-first-quarter

ARWR: Catalyst-Rich 2023…

Wed, February 8, 2023 at 11:34 AM
finance.yahoo.com/news/arwr-catalyst-rich-2023-103400004.html

Arrowhead Pharmaceuticals Gains Full Rights to NASH Candidate ARO-PNPLA3 with Promising Phase 1 Results

Wed, February 15, 2023 at 1:30 PM
finance.yahoo.com/news/...ls-gains-full-rights-123000705.html

Ich könnte mir vorstellen das Arrowhead eine Forschungsallianz mit Novartis eingeht?
Auf eier Folie von der JP Morgen Konferenz steht was von einem Platformdeal?

In der Art Morphosys-Novartis
www.morphosys.com/en/news/...-innovative-therapeutic-antibody

Arrowhead Announces Interim Results from Ongoing Phase 1/2 Study of ARO-C3 for Treatment of Complement Mediated Diseases

- Achieved Mean Reductions of 88% in C3 and 91% in AH50

February 28, 2023 07:30 AM Eastern Standard Time
www.businesswire.com/news/home/20230228005667/en/

Arrowhead Pharmaceuticals to Present at 43rd Annual Cowen Health Care Conference

Fri, March 3, 2023
PASADENA, Calif., March 03, 2023--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the respiratory/infections panel discussion on March 8, 2023, at 10:30 a.m. ET at the Cowen 43rd Annual Health Care Conference being held in Boston.
finance.yahoo.com/news/...-present-43rd-annual-123000016.html

Zahlen für Q1/23

• Umsatz 63 Mio. $
  
• Verlust 41 Mio. $
  
• Cash 618 Mio. $
  
• MK 2,72 Mrd. $
  

ir.arrowheadpharma.com/news-releases/...al-2023-first-quarter
ARWR ist bei mir gedanklich als Übernahmekandidat abgespeichert. Die Frage ist, wann der richtige Zeitpunkt ist hier einzusteigen.

Actual Study Start Date : March 6, 2023
Recruitment Status : Recruiting
clinicaltrials.gov/ct2/show/NCT05677971